Firm Events
District Court vs. PTAB: Strategic Forum Selection in Life Sciences Patent Disputes
December 10, 2026 | 12:00 PM – 1:00 PM ET
UPDATE
On February 19, the White House unveiled an interim final rule (IFR) to rescind all National Environmental Policy Act (NEPA) implementing regulations that the Council on Environmental Quality (CEQ) has promulgated since 1977. The IFR takes effect immediately and bypasses the usual public notice and comment process for rulemakings by invoking the “good cause” exception in the Administrative Procedures Act (APA)[1], although its publication in the Federal Register will trigger a 30-day public comment period.
Observers have long expected that the new administration would revisit the NEPA rules. The first Trump administration promulgated the first significant overhaul of CEQ’s NEPA regulations since they were initially codified in 1978. However, the full and formal repeal of CEQ’s NEPA regulations is both remarkable and somewhat predictable in the wake of Marin Audubon v. Federal Aviation Administration, No. 23-1067 (D.C. Cir. 2024), which jolted the environmental legal world by holding that CEQ never had the authority to promulgate NEPA regulations in the first place, and the second Trump administration’s “day one” orders to streamline environmental reviews for certain energy projects and revoke President Carter’s 1977 EO issued that originally directed CEQ to issue NEPA regulations. A subsequent decision in Iowa v. Council on Envtl. Quality, 1:24-cv-089 (D.N.D. Feb. 3, 2025) followed the lead of Marin Audubon in vacating the Biden administration’s Phase 2 NEPA rule based on CEQ’s lack of regulatory authority, and also limited the types of actions CEQ can take to set policy and priorities for other federal agencies in implementing NEPA. These events constituted the bulk of the Trump administration’s justification for the IFR.
Accompanying the IFR is a February 19, 2025 memorandum to all federal agencies directing them to do the following:
Revise or establish new NEPA implementation procedures consistent with the “Unleashing American Energy” executive order.
Not delay pending NEPA analyses while those NEPA procedures are being updated.
“Consider voluntarily relying on [the soon-to-be-rescinded] regulations in completing ongoing NEPA reviews or defending against” legal challenges.
Troutman Insights:
While this action follows naturally from the developments described in our February 6 alert, it introduces new regulatory uncertainty and an obvious litigation target.
NEPA Reviews: As we noted previously, federal agencies currently are in limbo regarding what regulations, if any, govern their statutorily mandated NEPA reviews. The Trump administration’s suggestion that agencies “voluntarily” continue to follow the old (and presumptively invalid) regulations for existing NEPA reviews and litigation appears to be a recognition that some guidance is needed while a new regulatory regime is being formulated. However, the voluntary nature of this directive could result in inconsistent approaches across agencies.
Litigation: It is possible that environmental groups will challenge the IFR as an inappropriate use of the APA “good cause” exception (which is typically reserved for emergencies) and seek an injunction requiring the White House to release any modifications to existing CEQ rules as a proposed rule. A drawn-out legal challenge could further unsettle the legal landscape for agencies and project proponents. Moreover, plaintiffs challenging existing and forthcoming permitting decisions will no doubt capitalize on this uncertainty to add an array of alternative NEPA claims to their complaints. Unless and until courts have settled on a new “doctrine” for how to handle such claims, every NEPA lawsuit could be a white-knuckle ride.
[1] 5 U.S.C. § 553(b)(B).
This just in
Firm Events
District Court vs. PTAB: Strategic Forum Selection in Life Sciences Patent Disputes
December 10, 2026 | 12:00 PM – 1:00 PM ET
Speaking Engagements
Performance on Trial: The Construction Manager’s Standard of Care Examined from All Angles
December 2, 2026 | 4:15 PM – 5:30 PM ET
The Hyatt Regency Huntington Beach
Huntington Beach, CA
Speaking Engagements
ACI’s 31st Annual Conference on Drug & Medical Device Litigation – 2026
December 2 – 3, 2026
New York Marriott Marquis
1535 Broadway, New York, NY 10036
Speaking Engagements
Fundamentals of Investment Adviser Regulation 2026
November 19, 2026 | 2:30 PM – 3:30 PM ET
PLI New York
1177 Avenue of the Americas, Entrance on 45th Street, New York, NY 10036